Clinical trial
Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor Gene Modified T Cells Targeting CD30 in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
NCT06850285 is registered in ClinicalTrials.gov with Shanxi Bethune Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor Gene Modified T Cells Targeting CD30 in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
- Lead sponsor
- Shanxi Bethune Hospital
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- September 5, 2025
- Completion date
- June 1, 2028
- Enrollment
- 15 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.